Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US

The US has imposed a 100% tariff on branded pharmaceuticals, with large firms given 120 days (smaller firms 180 days) to announce avoidance plans; companies that relocate manufacturing to the US may receive a reduced 20% tariff. Australia exports roughly $2bn of drugs to the US annually, with CSL (major plasma exporter) expected to be carved out; Canberra says it will not weaken its Pharmaceutical Benefits Scheme. The tariff risks modest downside for Australian pharma exporters and adds political pressure to US drug-pricing policy ahead of the November midterms.

Analysis

The headline tariff threat is a catalyst for a predictable but underappreciated re-allocation of capital along the pharma supply chain: firms that operate US manufacturing or CDMO capacity will see near-term demand re-rating as branded manufacturers seek tariff-avoidance options, while pure-exporters without US footprints will face an earnings multiple re-rating. Expect order backlogs for single-use consumables, vial/glass suppliers, cold-chain logistics and contract-packagers to jump in the next 3–12 months as companies either rush to buy capacity or pre-build inventories to avoid future tariff exposure.

Medium-term (12–36 months) consequences center on capex and M&A. Building greenfield sterile biologics plants takes years and several hundred million dollars; that makes acquisitions of existing US CDMOs and capacity expansions the faster, higher-probability path — a structural tailwind for acquisitive CDMOs and equipment vendors, and a headwind for margin-rich branded players that either concede pricing in the US or absorb tariffs. Currency and trade-agreement carve-outs create uneven competitive effects: firms domiciled in EU/Japan/Switzerland can selectively avoid the cost, creating winners/losers by domicile rather than by product quality.

Policy and political risk remain the main reversion channels. Negotiated exemptions, election-driven compromises or litigation could materially reduce the tariff’s potency within 3–9 months, which would compress near-term opportunities tied to reshoring. Conversely, if carve-outs are narrow, expect a multi-year shift in sourcing strategy; that would support CDMO capex plans and push valuations higher for suppliers with ready-to-scale US capacity.

Key Decisions for Investors

• Long Catalent (CTLT) — buy 6–12 month core position or call-spread (buy 12-month $20 calls / sell $28 calls) to capture accelerated CDMO demand; upside ~30–50% if reshoring deals accelerate, downside ~20% if carve-outs neutralize tariffs.
• Long Thermo Fisher (TMO) — initiate a 9–18 month call spread (buy 18-month $600 calls / sell $720 calls) to play higher consumables/equipment demand and supply-chain restocking; expect 2:1 reward:risk if industrial capex for biologics accelerates.
• Long Teva Pharmaceuticals (TEVA) or other large generics (selective) — buy 6–12 month calls or add to equity exposure to capture displacement of branded volume and pricing arbitrage; payoff high if policy preserves generic exemptions, but cap position size given regulatory and margin risks.
• Pair trade for Australia exposure: long CSL (ASX:CSL) and hedge with AUD downside — buy CSL equity (defensive carve-out candidate) and purchase 3–12 month AUD put options to protect against weaker export denominated earnings; this offsets revenue FX risk while keeping exposure to a likely exemption beneficiary.